Social Media Ideas for American Society Of Clinical Oncology

Bringing Global Cancer Science Closer To Patients In Asia At 2026 ASCO Breakthrough

Leading researchers, clinicians, and healthcare professionals will gather this June at the American Society of Clinical Oncology’s (ASCO) Breakthrough meeting to discuss the opport...

ASCO, Ryght AI team up for breast cancer trial site selection

The American Society of Clinical Oncology (ASCO) and Ryght AI are teaming up to identify research sites for an ASCO clinical trial evaluating starting doses of CDK4/6 inhibitors in...

Researchers From NYU Langone Health's Perlmutter Cancer Center Present Latest Findings at 2026 ASCO Annual Meeting

NEW YORK, May 29, 2026 /PRNewswire/ -- Experts from NYU Langone Health's Perlmutter Cancer Center, a National Cancer Institute–designated Comprehensive Cancer Center, present their...

NYU Langone Health’s Perlmutter Cancer Center Researchers Unveil Latest Discoveries at 2026 ASCO Annual Meeting

At the forefront of oncology research, NYU Langone Health’s Perlmutter Cancer Center, a National Cancer Institute–designated Comprehensive Cancer Center, has unveiled a series of g...

Society updates colorectal cancer screening guideline

The American Cancer Society updated its colorectal cancer screening guideline to reflect molecular-based screening tests that received regulatory approval in the past few years.The...

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.

Why I’m So Down on ASCO

Why I’m So Down on ASCO Anonymous (not verified) Mon, 06/01/2026 - 14:43 pharmagather item url Why I’m So Down on ASCO pharmagather item...

<![CDATA[What’s Trending in Oncology? A Discussion Following ASCO 2026 with Anne Marie Robertson from EVERSANA]]>

Consensus on Hepatocellular Carcinoma Trial Design

In a landmark collaboration, four of the world’s leading liver and oncology societies—the European Association for the Study of the Liver (EASL), the American Association for the S...

Highlights of ASCO 2026: how is cancer care evolving? 

Labiotech heard from experts about the major trends and highlights in cancer care at ASCO 2026. The post Highlights of ASCO 2026: how is cancer care evolving?  appeared first on L...

Adjuvant aspirin does not improve survival in colorectal cancer

CHICAGO — Low-dose aspirin during adjuvant chemotherapy did not significantly reduce risk for recurrence among unselected patients with stage III colorectal cancer, according to ra...

Complex Messaging, Outstanding Designs: Our Top 10 Exhibits at ASCO 2026

The American Society of Clinical Oncology (ASCO) 2026 Annual Meeting brought together more than 40,000 professionals at McCormick Place in Chicago May 29 through June 2 to explore...

ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting

Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, BioNTech, Eli Lilly and Moderna.

As Akeso takes center stage at ASCO, China biotech industry cements its coming of age

In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a cell therapy that w...

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple...

First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups

Most cancer survivors do not get lifestyle advice from clinicians

Only a third of cancer survivors receive advice on weight control and improving their diet from health care professionals, and less than half are informed about the benefits of phy...

The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentati...

CHENGDU, China, May 29, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinica...

UK3CR joins CCTG and EORTC in welcoming G7 commitment to accelerate global progress against cancer

Published: 24 June 2026 The Canadian Cancer Trials Group (CCTG), the European Organisation for Research and Treatment of Cancer (EORTC), and the UK Collaborative for Cancer Clinic...

ASCO: Will New Drugs Demonstrate Benefits Over Generics?

ASCO: Will New Drugs Demonstrate Benefits Over Generics? Anonymous (not verified) Sun, 05/31/2026 - 14:42 pharmagather item url ASCO: Will New Drugs Demons...

Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Bene...

Latest long-term analysis, including more than three years of follow-up data of patients with Grade 2 IDH-mutant glioma treated with VORANIGO® (vorasidenib), will be presented in a...

Nursing Insights: ASCENT-04 Results and Toxicity Management From ASCO

From: oncnursingnews.com The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting has brought transformative data for the treatment of metastatic triple-negative breast...

BIO 2026: How a gut feeling transformed cancer treatment forever

Dr. Israel Lowy remembers the days when he and his oncology immunotherapy colleagues were assigned tables in the distant east wing of the American Society of Clinical Oncology conf...

ASCO: Revolution Medicines confident in RAS leadership as rivals square up

This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data dro...

ACG cautions new CRC screening guideline may mislead patients

ACG has issued a statement urging clinicians to interpret American Cancer Society’s revised colorectal cancer screening guidance with caution.In the statement, ACG expressed concer...